Login to Your Account

Pharma dealmaking and collaboration shine brightly through the fog

By Cormac Sheridan
Staff Writer

Monday, November 2, 2015

MUNICH – The value of up-front payments in global biopharma licensing agreements is still climbing, and global M&A spending on R&D-stage companies so far in 2015 is the best in more than a decade.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription